Biosimilar Sponsors Can Avoid Patent Dance, But Innovators Win Extra Exclusivity
This article was originally published in The Pink Sheet Daily
Executive Summary
Sandoz says it will launch Zarxio Sept. 2 as Federal Circuit rules 180-day notice of launch to Amgen must follow FDA approval.